Skin Cancer Advisor - Schwartz - Cancer Therapy Advisor

Skin Cancer Advisor – Schwartz

Chapter 2

Should Patients With Melanoma Receive Targeted Therapy or Immunotherapy First?

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, discusses the current debate about whether patients with melanoma should receive targeted therapy or immunotherapy first.

Chapter 3

Melanoma: Checkpoints in the Pipeline

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, describes new receptors and checkpoints that oncologists may be able to manipulate to aid in the treatment of metastatic melanoma.

Chapter 4

Targeting Therapy for Melanoma Subtypes

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, describes how different varieties of melanoma are caused by different oncogenes, including BRAF, NRAS, and KIT.

Chapter 5

Melanoma: Targetable Genes in the Pipeline

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, discusses oncogenes present in melanoma that may be targetable with novel agents in development.

Chapter 6

Clinical Trials in Melanoma

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, discusses the benefits of clinical trials for patients with metastatic melanoma.